Latest News for: gsk
Edit
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans (Form 6-K) (GSK plc)
Public Technologies 23 Dec 2025
Edit
The Maryville Daily Times
22 Dec 2025
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Edit
Samsung Biologics to buy US drug production facility from GSK for $280 million
The Times of India 22 Dec 2025
Edit
Samsung Biologics takes over bio plant in Maryland from GSK
Korea Times 22 Dec 2025
Contract biopharmaceutical manufacturer Samsung Biologics has secured its first manufacturing base in the United States, acquiring the plant of Human Genome Sciences from global drug giant GSK for $280 million ... Until now, th .
Edit
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Washington Blade 20 Dec 2025
... Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Edit
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment ...
Nasdaq Globe Newswire 19 Dec 2025
... bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S.
Edit
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that ...
Wall Street Journal 19 Dec 2025
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return ... .
Edit
Caledonian Record
18 Dec 2025
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases ....
Edit
Transaction in own shares (Form 6-K) (GSK plc)
Public Technologies 18 Dec 2025
GSK plc published this content on December 18, 2025, and is solely responsible ...
Edit
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries (Form 8-K) (Camp4 Therapeutics Corporation)
Public Technologies 18 Dec 2025
) CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries ... GSK will be responsible for the further development and commercialization of ASO drug candidates identified through the collaboration.
Edit
U.S. FDA approves GSK's twice-yearly asthma drug
The Hindu 17 Dec 2025
The drug is the first biologic cleared for twice-yearly dosing ....
Edit
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma (GSK plc)
Public Technologies 17 Dec 2025
Edit
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma (Form 6-K) (GSK plc)
Public Technologies 17 Dec 2025
Edit
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (Form 6-K) (GSK plc)
Public Technologies 16 Dec 2025
GSK plc ... GSK plc (LSE/NYSE. GSK) today announced the marketing authorisation of Exdensur (depemokimab) by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) ... About GSK in respiratory ... About GSK ... Find out more at gsk.com. GSK enquiries.
Edit
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (GSK plc)
Public Technologies 15 Dec 2025
GSK plc (LSE/NYSE. GSK) today announced the marketing authorisation of Exdensur (depemokimab) by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) ... GSK said ... About GSK in respiratory.
- 1
- 2
- Next page »